Product information and disease descriptionProduct descriptionProduct information
Product comparison
26 evidence topics · 11 sources
Competing products and development programs in uveal melanoma named by the sponsor
Treatments used in practice for advanced uveal melanoma: NICE committee description
Treatments used in practice for metastatic uveal melanoma: CADTH description of off-label immunotherapy
Tebentafusp label: HLA-A∗02:01-positive indication and genotyping requirement
Tebentafusp label: weekly intravenous step-up dosing until progression
Tebentafusp label: administration setting, post-infusion monitoring, and two-step dilution
Tebentafusp label: boxed warning for cytokine release syndrome and its incidence in IMCgp100-202
Tebentafusp label: skin reaction and liver enzyme warnings in IMCgp100-202
Tebentafusp label: IMCgp100-202 design and population of 378 participants
Tebentafusp label: IMCgp100-202 efficacy results versus investigator’s choice
| Outcome | KIMMTRAK (N=252) | Investigator’s choice of pembrolizumab, ipilimumab, or dacarbazine (N=126) |
|---|---|---|
| Overall survival, number of deaths (%) | “87 (34.5%)” | “63 (50%)” |
| Overall survival, median in months (95% CI) | “21.7 (18.6, 28.6)” | “16 (9.7, 18.4)” |
| Progression-free survival, median in months (95% CI), final analysis | “3.3 (3, 5)” | “2.9 (2.8, 3)” |
| Objective response rate (95% CI), not formally tested | “9.1% (5.9, 13.4)” | “4.8% (1.8, 10.1)” |
| Complete response | “1 (0.4%)” | “0” |
| Partial response | “22 (8.7%)” | “6 (4.8%)” |
| Comparison, KIMMTRAK versus investigator’s choice | Hazard ratio (95% CI) |
|---|---|
| Overall survival, prespecified interim analysis, stratified by LDH status | “0.51 (0.37, 0.71)” |
| Progression-free survival, final analysis, stratified by LDH status | “0.73 (0.58, 0.94)” |
Tebentafusp label: serious adverse reactions and discontinuation among patients who received KIMMTRAK in IMCgp100-202
Melphalan hepatic delivery system label: liver-directed indication restricted by hepatic tumor burden
Melphalan hepatic delivery system label: intra-arterial dosing every 6 to 8 weeks for up to 6 infusions
Melphalan hepatic delivery system label: boxed warning, general anesthesia, and REMS-certified settings
Melphalan hepatic delivery system label: FOCUS single-arm efficacy in 91 treated participants
| Outcome in the FOCUS trial | HEPZATO (N=91) |
|---|---|
| Objective response rate (95% CI) | “36.3% (26.4, 47.0)” |
| Complete response | “7.7%” |
| Partial response | “28.6%” |
| Number of responders | “n= 33” |
| Median duration of response, months (95% CI) | “14.0 (8.3, 17.7)” |